Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.38 |
| ▸ | MTOR | P42345 | 12/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 10/20 | 0.36 |
| ▸ | ATR | Q13535 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617191 | 0.91 | PDE1B (0.37) | EGFRMTORPDE1APDE1BPDE1C | |
| SCHEMBL617415 | 0.88 | EGFR (0.36) | EGFRPIK3CAMTORPDE1APDE1B | |
| SCHEMBL614876 | 0.85 | L3MBTL1 (0.36) | EGFRPDE1APDE1BPDE1C | |
| SCHEMBL614950 | 0.84 | EGFR (0.35) | EGFRPIK3CAMTORPDE1APDE1B | |
| SCHEMBL618143 | 0.81 | EGFR (0.34) | EGFRPDE1APDE1BPDE1C | |
| SCHEMBL617404 | 0.80 | CHRM1 (0.39) | MTOR | |
| SCHEMBL14875392 | 0.79 | ESR1 (0.38) | EGFRPDE1APDE1BPDE1CATM | |
| SCHEMBL15215831 | 0.78 | L3MBTL1 (0.33) | EGFRPDE1APDE1BPDE1C | |
| SCHEMBL3807849 | 0.74 | PDE4A (0.39) | EGFRPDE1APDE1BPDE1CMAPK1 | |
| SCHEMBL617714 | 0.73 | PDE1B (0.35) | EGFRPIK3CAMTORPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421366-B1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | CHRM1, CNR1, CHRNA7 | EGFR 2672/4885PIK3CA 1114/4885MTOR 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.